[Federal Register: September 14, 2006 (Volume 71, Number 178)]
[Notices]
[Page 54297]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14se06-54]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of a Complete T-Cell
Receptor Recognizing MART-1 Peptide Restricted by HLA-A2, Incorporated
in a Continuous T-Lymphocyte Cell Line Developed or Owned by Licensee
To Treat Cancer
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
patent 5,830,755 filed March 27, 1995 [HHS Ref. No. E-093-1995/0-US-01]
and Australian Patent 709122 filed March 27, 1996 [HHS Ref. No. E-093-
1995/0-AU-03], entitled T-Cell Receptors and Their Use in Therapeutic
and Diagnostic Methods, to CellCure A/S, which is located in Aarhus,
Denmark. The patent rights in these inventions have been assigned to
the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of a complete T-cell
receptor MART-1 peptide restricted by HLA-A2 incorporated into a
continuous T-Lymphocyte cell line developed or owned by licensee to
treat cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
November 13, 2006 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; telephone: (301) 451-7337; facsimile: (301) 402-0220; e-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology describes the composition and
use of nucleic acid sequences that encode polypeptides capable of
forming a T-cell receptor (TCR) in a genetically engineered cell.
Specifically, these nucleic acid sequences will encode TCR's specific
to tumor associated antigens (TAA), MART-1. T-Cells engineered with
these tumor associated antigen specific TCRs show specific immune
responses against TAA expressing cancer cells. Additionally, a method
of treating or preventing cancer by administrating the above described
TCRs is also disclosed.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Date: September 7, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-15216 Filed 9-13-06; 8:45 am]
BILLING CODE 4167-01-P